Clinical Trial Update: SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer [Phase 2]

View source ↗

Summary

Phase 2 study of SANGUINATE for leg ulcers in sickle cell disease has completed, reporting results from the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leg Ulcers
• Sickle Cell Disease

Drugs mentioned

• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Leg Ulcer | Phase 2 | Status: COMPLETED